Arch Biopartners Inc. (TSXV:ARCH)
Canada · Delayed Price · Currency is CAD 0.9700
+0.0200 (2.11%)
Oct 24, 2025, 2:12 PM EDT
Arch Biopartners Revenue
Arch Biopartners had revenue of 158.08K CAD in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to -84.71K, down -106.12% year-over-year. In the fiscal year ending September 30, 2024, Arch Biopartners had annual revenue of 2.12M with 6.97% growth.
Revenue (ttm)
-84.71K
Revenue Growth
-106.12%
P/S Ratio
-743.27
Revenue / Employee
n/a
Employees
n/a
Market Cap
62.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 2.12M | 138.21K | 6.97% |
| Sep 30, 2023 | 1.98M | 1.02M | 105.63% |
| Sep 30, 2022 | 964.68K | -2.92M | -75.18% |
| Sep 30, 2021 | 3.89M | 3.82M | 5,625.22% |
| Sep 30, 2020 | 67.89K | -25.99K | -27.69% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Curaleaf Holdings | 1.75B |
| dentalcorp Holdings | 1.62B |
| Trulieve Cannabis | 1.62B |
| Green Thumb Industries | 1.57B |
| Extendicare | 1.51B |
| Verano Holdings | 1.16B |
| WELL Health Technologies | 1.12B |
| Sienna Senior Living | 929.68M |
Arch Biopartners News
- 5 weeks ago - Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD) - GlobeNewsWire
- 2 months ago - Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury - GlobeNewsWire
- 3 months ago - Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI) - GlobeNewsWire
- 6 months ago - Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) - GlobeNewsWire
- 8 months ago - Arch Biopartners Arranges Non-Brokered Private Placement - GlobeNewsWire
- 8 months ago - Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI) - GlobeNewsWire
- 9 months ago - Shares for Interest Debt Settlement - GlobeNewsWire
- 10 months ago - Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI) - GlobeNewsWire